203 related articles for article (PubMed ID: 34301921)
1. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Zhang H; Zheng Z; Zhang R; Yan Y; Peng Y; Ye H; Lin L; Xu J; Li W; Huang P
Cell Death Dis; 2021 Jul; 12(8):731. PubMed ID: 34301921
[TBL] [Abstract][Full Text] [Related]
2. ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.
Zhou Z; Jiang H; Tu K; Yu W; Zhang J; Hu Z; Zhang H; Hao D; Huang P; Wang J; Wang A; Xiao Z; He C
J Exp Clin Cancer Res; 2019 Jan; 38(1):18. PubMed ID: 30646949
[TBL] [Abstract][Full Text] [Related]
3. Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.
Wang Y; Xie BH; Lin WH; Huang YH; Ni JY; Hu J; Cui W; Zhou J; Shen L; Xu LF; Lian F; Li HP
Oncogene; 2019 Jun; 38(25):4948-4961. PubMed ID: 30842588
[TBL] [Abstract][Full Text] [Related]
4. Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration.
Chen LB; Xu JY; Yang Z; Wang GB
World J Gastroenterol; 2007 Nov; 13(43):5718-24. PubMed ID: 17963297
[TBL] [Abstract][Full Text] [Related]
5. [Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2].
Xu JY; Chen LB; Xu JY; Yang Z; Wei HY; Xu RH
Ai Zheng; 2006 May; 25(5):526-32. PubMed ID: 16687068
[TBL] [Abstract][Full Text] [Related]
6. Endoplasmic reticulum resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway.
Yang S; Yang C; Yu F; Ding W; Hu Y; Cheng F; Zhang F; Guan B; Wang X; Lu L; Rao J
Cell Death Dis; 2018 Oct; 9(11):1105. PubMed ID: 30377291
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
8. [Induction of SMYD3 by hepatitis B virus X gene in HepG2 cells].
Yang L; Ren J; He J; Chen LB
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):297-300. PubMed ID: 19403031
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
Fei X; Ma Y; Liu X; Meng Z
Tohoku J Exp Med; 2017 Nov; 243(3):219-226. PubMed ID: 29187705
[TBL] [Abstract][Full Text] [Related]
10. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma.
He C; Xu J; Zhang J; Xie D; Ye H; Xiao Z; Cai M; Xu K; Zeng Y; Li H; Wang J
Hum Pathol; 2012 Sep; 43(9):1425-35. PubMed ID: 22406368
[TBL] [Abstract][Full Text] [Related]
11. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma.
Zhu Y; Zhu MX; Zhang XD; Xu XE; Wu ZY; Liao LD; Li LY; Xie YM; Wu JY; Zou HY; Xie JJ; Li EM; Xu LY
Hum Pathol; 2016 Jun; 52():153-63. PubMed ID: 26980013
[TBL] [Abstract][Full Text] [Related]
12. Interaction of the hepatitis B virus X protein with the lysine methyltransferase SET and MYND domain-containing 3 induces activator protein 1 activation.
Hayashi M; Deng L; Chen M; Gan X; Shinozaki K; Shoji I; Hotta H
Microbiol Immunol; 2016 Jan; 60(1):17-25. PubMed ID: 26616333
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine-1-phosphate Receptor-1 Promotes Vascular Invasion and EMT in Hepatocellular Carcinoma.
Yokota T; Nojima H; Kuboki S; Yoshitomi H; Furukawa K; Takayashiki T; Takano S; Ohtsuka M
J Surg Res; 2021 Mar; 259():200-210. PubMed ID: 33307511
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma.
Binh MT; Hoan NX; Giang DP; Tong HV; Bock CT; Wedemeyer H; Toan NL; Bang MH; Kremsner PG; Meyer CG; Song LH; Velavan TP
Sci Rep; 2020 Feb; 10(1):2797. PubMed ID: 32071406
[TBL] [Abstract][Full Text] [Related]
15. Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma.
Chen Y; Yang S; Hu J; Yu C; He M; Cai Z
PLoS One; 2016; 11(5):e0154939. PubMed ID: 27183310
[TBL] [Abstract][Full Text] [Related]
16. The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population.
Li RD; Tang YH; Wang HL; Yang D; Sun LJ; Li W
Pathol Res Pract; 2018 May; 214(5):625-630. PubMed ID: 29691085
[TBL] [Abstract][Full Text] [Related]
17. SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non‑small cell lung cancer.
Li J; Zhao L; Pan Y; Ma X; Liu L; Wang W; You W
Int J Oncol; 2020 Sep; 57(3):756-766. PubMed ID: 32705243
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.
Sui CJ; Zhou YM; Shen WF; Dai BH; Lu JJ; Zhang MF; Yang JM
J Mol Med (Berl); 2016 Nov; 94(11):1281-1296. PubMed ID: 27380494
[TBL] [Abstract][Full Text] [Related]
19. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
Cock-Rada AM; Medjkane S; Janski N; Yousfi N; Perichon M; Chaussepied M; Chluba J; Langsley G; Weitzman JB
Cancer Res; 2012 Feb; 72(3):810-20. PubMed ID: 22194464
[TBL] [Abstract][Full Text] [Related]
20. High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
Wang G; Huang Y; Yang F; Tian X; Wang K; Liu L; Fan Y; Li X; Li L; Shi B; Hao Y; Xia C; Nie Q; Xin Y; Shi Z; Ma L; Xu D; Liu C
Aging (Albany NY); 2020 Feb; 12(3):2030-2048. PubMed ID: 32007952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
